EGFR and colorectal cancer: EGFR copy number gain ≥4.0/nucleus confers significantly improved PFS with anti-EGFR therapy (HR 0.2, 95% CI: 0.1–0.5) in colorectal cancer patients refractory to chemotherapy [87].